Zimmer Biomet Holdings, INC

Zimmer Biomet announces leadership promotions and a departure to streamline its Americas and Global Business Group organizations for enhanced focus and agility.

Zimmer Biomet announced second quarter 2026 financial results, with net sales increasing 4.8% and the company raising its full-year guidance.

Zimmer Biomet Holdings, Inc. has entered into new five-year and 364-day revolving credit agreements totaling $2.75 billion, replacing previous facilities.

Zimmer Biomet shareholders re-elected ten directors and ratified the appointment of PricewaterhouseCoopers LLP at the 2026 annual meeting.

Zimmer Biomet announced an increased share repurchase program, now targeting up to $1 billion in fiscal year 2026, a $250 million rise from previous expectations.

Zimmer Biomet Holdings, Inc. announced the resignation of its Chief Financial Officer, Suketu Upadhyay, effective April 28, 2026, with Paul Stellato appointed as interim CFO.

Zimmer Biomet Holdings, Inc. announced a 4.8% increase in net sales for the second quarter of 2026, driven by acquisitions, favorable currency, and product demand.

Zimmer Biomet reported a 9.3% increase in Q1 2026 net sales to $2.09 billion, driven by the Paragon 28 acquisition and strong demand for robotic and surgical technologies.

Zimmer Biomet Holdings, Inc. reported a 9.7% increase in net sales for the third quarter of 2025, driven by strategic acquisitions and market growth, despite a decline in net earnings.

Zimmer Biomet Holdings, Inc. reported a 7% increase in net sales for Q2 2025, driven by acquisitions and market growth, but net earnings significantly declined due to acquisition-related costs and higher interest expenses.

Zimmer Biomet's Q1 2025 net sales rose by 1.1% year-over-year, but the company anticipates lower net earnings for the year due to acquisition and integration costs related to Paragon 28.

Zimmer Biomet's Q3 2024 results show a net sales increase of 4.0% year-over-year, despite operational challenges from a new ERP system implementation.

Zimmer Biomet's 2024 results show a net sales increase of 3.8% and the company plans to acquire Paragon 28, Inc.

Zimmer Biomet has updated its executive change in control severance agreements to provide for either a reduction in payments to avoid excise tax or full payment, whichever results in a better after-tax outcome for the executive.

Michael J. Farrell, a Director of Zimmer Biomet Holdings, Inc., received 417 shares of common stock on September 30, 2026.

Robert Hagemann, a Director of Zimmer Biomet Holdings, Inc., received 306 shares of common stock on September 30, 2026.

Arthur J Higgins, a Director of Zimmer Biomet Holdings, Inc., received 306 shares of common stock on September 30, 2026.

Louis Shapiro, a Director of Zimmer Biomet Holdings, Inc., received 153 shares of common stock on September 30, 2026.

Maria Teresa Hilado, a Director of Zimmer Biomet Holdings, Inc., received 376 shares of common stock on September 30, 2026.

Devdatt Kurdikar, a Director of Zimmer Biomet Holdings, Inc., received 174 shares of common stock on September 30, 2026.

Zimmer Biomet Holdings, Inc. filed its definitive proxy statement for the 2026 annual meeting, outlining strong 2025 financial performance, executive compensation, and board recommendations on key governance matters.

Zimmer Biomet Holdings, Inc. announces its 2024 Annual Meeting of Stockholders to be held on May 10, 2024, outlining key voting items and access to proxy materials.

Zimmer Biomet releases its proxy statement, outlining key proposals for the upcoming 2025 annual meeting, including director elections, auditor ratification, and executive compensation.

Zimmer Biomet Holdings, Inc. announces its 2024 Annual Meeting of Stockholders to be held on May 10, 2024, outlining key voting items including the election of directors, ratification of the independent auditor, executive compensation, and approval of the amended Employee Stock Purchase Plan.

Zimmer Biomet's proxy statement details the company's corporate governance framework, executive compensation practices, and proposals for the upcoming annual shareholder meeting.

Zimmer Biomet Holdings, Inc. and its subsidiary, Honey Badger Merger Sub, Inc., have entered into a definitive agreement to acquire Monogram Technologies Inc. for a combination of cash and contingent value rights, valuing common stock at up to $16.41 per share.

Dodge & Cox reports a beneficial ownership of 24,124,735 shares, representing 12.5% of Zimmer Biomet Holdings, Inc. common stock as of June 30, 2026.

Capital International Investors has reported a beneficial ownership of 6.4% in Zimmer Biomet Holdings, Inc., holding 12,438,366 shares.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4.1% of Zimmer Biomet Holdings Inc. common stock as of March 31, 2026.

Vanguard Capital Management has filed a Schedule 13G reporting a 7.54% beneficial ownership stake in Zimmer Biomet Holdings Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Zimmer Biomet Holdings Inc. following an internal corporate realignment.

Dodge & Cox, an investment adviser, has reported an increased passive beneficial ownership stake of 11.2% in Zimmer Biomet Holdings, Inc. as of June 30, 2025.